Novartis India Revenue and Competitors
Estimated Revenue & Valuation
- Novartis India's estimated annual revenue is currently $268.1M per year.
- Novartis India's estimated revenue per employee is $140,000
Employee Data
- Novartis India has 1915 Employees.
- Novartis India grew their employee count by 10% last year.
Novartis India's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Global Analytical Science & Technology Manager | Reveal Email/Phone |
2 | Associate Manager, Artwork Operations | Reveal Email/Phone |
3 | Global Benchmarking Lead | Reveal Email/Phone |
4 | Analytical Project Leader | Reveal Email/Phone |
What Is Novartis India?
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world. See our community guidelines: http://bit.ly/35zXur6
keywords:N/A
N/A
Total Funding
1915
Number of Employees
$268.1M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Novartis India News
Dr. Reddy's on Friday said it has entered into an agreement with Novartis to acquire the cardiovascular brand Cidmus in India for Rs 456...
Novartis (NVS) has signed an agreement to sell cardiovascular medicine brand Cidmus in India to Dr. Reddy's Laboratories (NYSE:RDY) for $61...
Dr Reddy's Laboratories on Friday said it has inked a pact with. Novartis AG to acquire the cardiovascular medicine brand Cidmus in India...
Other Companies in Mumbai
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $595.7M | 1934 | 16% | N/A |
#2 | $395.4M | 1967 | 26% | N/A |
#3 | $801.4M | 1974 | 83% | N/A |
#4 | $359.5M | 1975 | 3% | N/A |
#5 | $35M | 1988 | 10% | N/A |